Use of a synthetic control arm drawn from historical clinical trial data could provide better information about a new investigational agent’s safety and efficacy than single-arm studies and allow sponsors to conduct randomized trials that are smaller, or with more patients assigned to the investigational drug.
However, such an approach should not be considered a replacement for randomized, controlled trials when they are feasible to do, US FDA officials said at the